Fetal growthretardation: modern view on pharmacological correction

Purpose. Comparative analysis of the effectiveness of pharmacological correction of fetal growth retardation using monotherapy with diosmin and dipyridamole.

Materials and methods. A retrospective and prospective examination of 160 pregnant women with a singleton pregnancy at a gestational age of 28 to 36 weeks with a confirmed diagnosis of fetal growth restriction was conducted. An extensive collection and analysis of anamnesis, general clinical and obstetric-gynecological examination, laboratory and ultrasound methods were carried out. Newborns were assessed using Apgar scores at birth and 5 min later. In the early neonatal period, congenital and incident pathological syndromes were assessed.

Results. In patients receiving diosmin, a decrease in the resistance index of the right and left uterine arteries was achieved to 0.42±0.002 and 0.45±0.002, respectively, and for the umbilical cord artery to 0.52±0.02, which is significantly lower than in the group of patients taking dipyridamole. A positive effect of diosmin on the intrauterine state of the fetus was revealed, which is realized in the form of an increase in its compensatory abilities to adapt to chronic hypoxia in a significantly higher percentage of cases compared to dipyridamole.

Conclusion. The data obtained demonstrate the difference in the pharmacokinetics of these drugs: diosmin equally improves both maternal and fetal blood flow, which is most valuable in the treatment of fetal growth restriction, while dipyridamole affects only uterine blood flow.

1. Degtyareva E. A., Zakharova O. A., Kufa M. A. et al. The efficacy of prognosis and early diagnostics of fetal growth retardation. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2018; 63 (6): 37–45. (In Russ.). DOI: 10.21508/1027‑4065‑2018‑63‑5‑37‑45

2. Klycheva O. I., Khuraseva A. B. Comparative analysis of pharmacological efficacy of angioprotective agents in the treatment of fetal growth retardation syndrome. Kursk Scientific and Practical Bulletin «Man and His Health». 2017; (3): 43–48. (In Russ.). DOI: 10.21626/vestnik/2017–3/07

3. Logutova L. S., Petrukhin V. A., Akhvlediani K. N. et al. Efficacy of angioprotectors in the treatment of pregnant women with placental insufficiency. Russian Bulletin of Obstetrician-Gynecologist. 2010; 7 (2): 45–50. (In Russ.).

4. Goryunova A. G., Simonova M. S., Murashko A. V. Fetal growth retardation syndrome and adaptation of placenta. V. F. Snegirev Archives of Obstetrics and Gynecology, Russian journal. 2016; 3 (2): 76–80. (In Russ.). DOI: 10.18821/2313‑8726‑2016‑3‑2‑76‑80

5. Strizhenok E. A., Gudkov I. V., Strachunskii L. S. Use of drugs during pregnancy: results of a multicenter pharmacoepidemiological study. Clinical Microbiology and Antimicrobial Chemotherapy. 2007; 9 (2): 162–175. (In Russ.).

6. Sukhikh G. T. The problem of pharmacotherapy during pregnancy. Federal directory. Social development and demography. 2011: 253–256. (In Russ.).

7. Bikmetova E. S., Trishkin A. G., Artymuk N. V. Fetal growth retardation. Frequency, risk factors. Mother and child in Kuzbass. 2012; 1 (1): 27–31. (In Russ.).

8. Prodanova E. V., Rogozhina I. E., Chekhonatskaya M. L. et al. Comparative Doppler assessment of the effectiveness of therapy for pregnant women with fetoplacental insufficiency. Russian Bulletin of Obstetrician-Gynecologist. 2011; 11 (2): 79–82. (In Russ.).

9. Sokolova T. M., Marinkin I. O., Kuleshov V. M. et al. Experience with the use of dipyridamole in a group of pregnant women at high risk of perinatal pathology. Medical Council .2018; 7: 98–100. (In Russ.). DOI: 10.21518/2079-701X‑2018‑7‑98‑100

10. Boisnic S, Branchet M.C., Gouhier-Kodas C., Verriere F., Jabbour V. Anti-inflammatory and antiradical effects of a 2 % diosmin cream in a human skin organ culture as model. J Cosmet Dermatol. 2018;17:848–854. https://doi.org/10.1111/jocd.12778

11. Boisnic S., Branchet M.-C., Quioc-Salomon B., Doan J., Delva C., Gendron C. Anti-Inflammatory and Antioxidant Effects of Diosmetin‑3-O – D-Glucuronide, the Main Metabolite of Diosmin: Evidence from Ex Vivo Human Skin Models. Molecules 2023; 28: 5591. https://doi.org/10.3390/molecules28145591